"An Integrative Multiomics Approach To Multiple Myeloma"- John Schieszer
When practicing precision oncology for multiple myeloma, clinicians currently match specific DNA mutations to the optimal targeted therapy. However, it may be time to think about incorporating genome-wide RNA profiles to better guide therapy. A new trial published in JCO Precision Oncology found that a comprehensive RNA and DNA sequencing platform may benefit late-stage and drug-resistant multiple myeloma patients by determining which agents may work best for them. “Our study demonstrated that tumor sequencing can help guide treatment decisions patients with relapsed/refractory multiple myeloma in a personalized manner. What was surprising was that the majority of patients who responded to the recommended treatment were treated based on their RNA expression, rather than on their DNA mutations,” said study investigator Alessandro Lagana, PhD, an assistant professor of genetics and genomic sciences at the Institute for Next Generation Healthcare and the Icahn Institute for Genomics and Multiscale Biology at the Icahn School of Medicine at Mount Sinai.
- Alessandro Lagana, PhD, Assistant Professor, Genetics and Genomic Sciences, The Institute for Next Generation Healthcare, Icahn Institute for Genomics and Multiscale Biology, Icahn School of Medicine at Mount Sinai